Hypoglycemics

Details Hypoglycemics Hypoglycemics

A - Human Necessities

61

K

A61K 38/23 (2006.01) A61K 31/155 (2006.01) A61K 31/64 (2006.01) A61K 38/22 (2006.01)

Patent

CA 2067738

2067738 9203148 PCTABS00010 Non-insulin dependent, or type 2, diabetes mellitus is treated by administration of a hypoglycemic agent that enhances plasma concentrations of amylin and of an amylin antagonist. The hypoglycemic agent can be a sulfonurea or a biguanide. The amylin antagonist can be an amylin or a calcitonin gene-related peptide having altered reactive sites or being cross-linked or truncated. Patients are also monitored for enhanced plasma concentrations of amylin following administration of hypoglycemic agents, and the effects of agents on the secretion of amylin in biological system such as a cell culture of islet beta cells is monitored by an assay.

Affiliated with

Also associated with

Rating

Hypoglycemics does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Hypoglycemics, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hypoglycemics will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1928890